Endologix(NASDAQ:ELGX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $47.463M. Analysts estimated a revenue of $48.690M. The revenues were -2.52% below the estimates. Earnings per share were $-0.22. The reported EPS was below estimates by -15.79%. Analysts had estimated an EPS of $-0.19.
Endologix (ELGX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.62% or 0.04 points. Due to strong positive momentum, the stock ended at $6.53, which is also near the day’s high of $6.85. The stock began the session at $6.47 and the volume stood at 31,64,480 shares. The 52-week high of the shares is $14.495 and the 52 week low is $4.78. The company has a current market capitalization of $540 M and it has 8,26,91,080 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Dec 15, 2016, Iii Thomas F Zenty (director) purchased 3,000 shares at $6.51 per share price.Also, On Dec 15, 2016, John D Mcdermott (CEO) purchased 10,000 shares at $6.67 per share price.On Dec 15, 2016, Vaseem Mahboob (CFO) purchased 20,000 shares at $6.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Endologix Inc. is engaged in developing manufacturing marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS) its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.